Rho Ventures V L.P. 13D and 13G filings for NGM Biopharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-13 12:57 pm Sale | 2022-12-31 | 13G | NGM Biopharmaceuticals, Inc. NGM | Rho Ventures V L.P. | 430,783 0.500% | -3,372,487 (-88.67%) | Filing |
| 2021-02-16 2:53 pm Purchase | 2020-12-31 | 13G | NGM Biopharmaceuticals, Inc. NGM | Rho Ventures V L.P. | 3,803,270 5.500% | 12,604 (+0.33%) | Filing |
| 2021-02-12 5:25 pm Purchase | 2020-12-31 | 13G | NGM Biopharmaceuticals, Inc. NGM | Rho Ventures V L.P. | 3,790,666 5.500% | 6,000 (+0.16%) | Filing |